David A. Nathanson,Wilson X. Mai,Michael E. Jung,Peter M. Clark,Timothy F. Cloughesy,Gyudong Kim,Jonathan Tsang,Lorenz Urner
申请号：
US16651256
公开号：
US20200290978A1
申请日:
2018.09.26
申请国别(地区):
US
年份:
2020
代理人:
摘要：
The present disclosure relates to compounds that are capable penetrating to the blood brain barrier to modulate the activity of EGFR tyrosine kinase. The disclosure further relates to methods of treating glioblastoma and other EGFR mediated cancers. The disclosure further relates to methods of treating glioblastoma and other EGFR mediated cancers that have been determined to have altered glucose metabolism in the presence of inhibitors. The present disclosure also provides methods of administering to a subject a glucose metabolism inhibitor and a cytoplasmic p53 stabilizer.
